Latest news with #JasonGerberry
Yahoo
12 hours ago
- Business
- Yahoo
BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT
Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Relay Therapeutics, Inc. (NASDAQ:RLAY) on June 3 and set a price target of $17.00. The rating update came after the company announced updated interim clinical data for RLY-2608 on June 2. A chemist arranging containers of compounds, ready for the commercialization process. RLY-2608 is the first known investigational allosteric, pan-mutant, and isoform-selective inhibitor of PI3Kα. The updated interim data remained consistent with the data previously shared in December 2024, showing a '10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer.' The data continues to support the planned pivotal study initiation in mid-2025. Relay Therapeutics, Inc. (NASDAQ:RLAY) is a clinical-stage precision medicine company that uses advanced computational and experimental technologies to innovate drug discovery. Its primary focus is on genetic disease indications and targeted oncology. The company's Dynamo platform integrates a range of cutting-edge experimental and computational approaches to understand protein structure and motion in drug discovery. While we acknowledge the potential of RLAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
2 days ago
- Business
- Yahoo
BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT
Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Relay Therapeutics, Inc. (NASDAQ:RLAY) on June 3 and set a price target of $17.00. The rating update came after the company announced updated interim clinical data for RLY-2608 on June 2. A chemist arranging containers of compounds, ready for the commercialization process. RLY-2608 is the first known investigational allosteric, pan-mutant, and isoform-selective inhibitor of PI3Kα. The updated interim data remained consistent with the data previously shared in December 2024, showing a '10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer.' The data continues to support the planned pivotal study initiation in mid-2025. Relay Therapeutics, Inc. (NASDAQ:RLAY) is a clinical-stage precision medicine company that uses advanced computational and experimental technologies to innovate drug discovery. Its primary focus is on genetic disease indications and targeted oncology. The company's Dynamo platform integrates a range of cutting-edge experimental and computational approaches to understand protein structure and motion in drug discovery. While we acknowledge the potential of RLAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
04-05-2025
- Business
- Yahoo
Organon price target lowered to $10 from $11 at BofA
BofA analyst Jason Gerberry lowered the firm's price target on Organon (OGN) to $10 from $11 and keeps an Underperform rating on the shares. The firm said the company cutting its dividend was a 'necessary evil' given the company's limited pipeline, adding that the move makes strategic sense given Organon's high leverage and need to diversify from Nexplanon risk. BofA noted that, following the quarterly update, its concern with the stock may not be enough of a reason tot build a new position in the stock. Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on OGN: Disclaimer & DisclosureReport an Issue Organon cuts quarterly dividend to 2c per share from 28c Organon falls -23.6% Organon falls -26.9% Organon falls -18.7% Organon reports Q1 adjusted EPS $1.02, consensus 89c Sign in to access your portfolio
